Key result
Canakinumab successfully manages steroid-dependent recurrent pericarditis in a child following anakinra anaphylaxis.
Why the study?
The efficacy and safety of canakinumab had not been assessed to date for steroid-dependent idiopathic recurrent pericarditis in patients developing an anaphylactic reaction to anakinra.
Does canakinumab successfully treat steroid-dependent idiopathic recurrent pericarditis in a patient with anaphylaxis to anakinra?
Case Report (n=1)
Does canakinumab successfully treat steroid-dependent idiopathic recurrent pericarditis in a patient with anaphylaxis to anakinra?
Canakinumab can be successfully used to manage steroid-dependent idiopathic recurrent pericarditis in children who experience anaphylaxis to anakinra.
May offer an alternative after anakinra anaphylaxis; hypothesis-generating case report requiring prospective trials.
Conventional algorithm for treatment of pericarditis and prevention of recurrences consists of non-steroid anti-inflammatory drugs and/or colchicine, followed by corticosteroids in resistant patients. Anakinra has emerged as a promising and safe treatment modality for steroid-dependent idiopathic recurrent pericarditis. However, the efficacy and safety of canakinumab, another anti-interleukin-1 agent, has not been assessed up to date. Herein, we present development of an anaphylactic reaction due to anakinra and a successful subsequent treatment with canakinumab for the first time in the literature.
No takes yet. Share an insight, caveat, or question.
Epçaçan et al. (2019) conducted a case report in steroid-dependent idiopathic recurrent pericarditis (n=1). canakinumab was evaluated on successful management of pericarditis. Canakinumab successfully managed steroid-dependent idiopathic recurrent pericarditis in a child following an anaphylactic reaction to anakinra.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: